Ipamorelin

Plain-English version: ipamorelin is a small synthetic peptide that acts like a "release" signal for your own growth hormone. Instead of injecting growth hormone directly, you inject a tiny amount of ipamorelin, and your pituitary gland responds by putting out a short pulse of the GH it already makes. Because it works with your body's own machinery, that GH pulse still passes through your normal feedback controls rather than flooding the system.

Chemically, ipamorelin is a pentapeptide — a chain of just five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2). It belongs to a family called growth hormone secretagogues (a "secretagogue" is simply a substance that makes a gland secrete something). Ipamorelin's specific target is the ghrelin receptor, also known as GHSR-1a, on the GH-producing cells of the pituitary.^[1]

It has a real pharmaceutical history. Ipamorelin was developed by Novo Nordisk in the 1990s and advanced into human clinical trials — including a Phase 2 study for postoperative ileus (the temporary shutdown of gut movement after abdominal surgery).^[4] Development did not continue to approval, and no ipamorelin drug product exists on the market today.

What sets ipamorelin apart from older peptides in its class is selectivity. Its defining paper described it as "the first selective growth hormone secretagogue" because, at doses that released GH, it did not meaningfully raise cortisol (a stress hormone), ACTH, or prolactin — a contrast with GHRP-6 (which drives intense hunger) and GHRP-2 (which also lifts prolactin and cortisol).^[1] That "clean pulse" reputation is the single biggest reason ipamorelin is so widely discussed.

Credibility check: ipamorelin is not approved by the FDA for any use, and it has not been shown to work in a positive human efficacy trial (more on that below). It is a research compound. For the broader legal picture, see Are Peptides Legal?

Takeaway first: ipamorelin mimics ghrelin (the "hunger hormone") at one specific receptor in the pituitary, and that triggers a burst of growth hormone. Unlike ghrelin itself and unlike older GH peptides, it does this without strongly switching on the pathways that raise cortisol, prolactin, and appetite.

The receptor it targets

Ipamorelin binds the growth hormone secretagogue receptor (GHSR-1a) — the same receptor the natural hormone ghrelin uses. When ipamorelin activates GHSR-1a on the pituitary's somatotroph cells (the cells that store and release GH), those cells fire off a pulse of growth hormone. In the original characterization, this was shown in isolated rat pituitary cells (in a dish) and confirmed in live rats and swine.^[1]

Why "selective" matters

The key finding from Raun and colleagues in 1998 was that ipamorelin released GH with a selectivity "comparable to GHRH itself" — meaning it did not significantly bump ACTH or cortisol at GH-releasing doses, unlike GHRP-6 and GHRP-2.^[1] In practical terms, that is the difference between a targeted GH signal and a messier hormonal ripple. This is the source of essentially every "cleanest secretagogue" claim you will read about ipamorelin — and it is a legitimate, cited finding, though it comes from preclinical (cell and animal) work.

A different pathway than GHRH peptides

Ipamorelin works through a different door than GHRH analogs such as sermorelin or CJC-1295:

• GHRH analogs (sermorelin, CJC-1295): bind the GHRH receptor and drive GH synthesis and release.
• Ipamorelin: binds the ghrelin receptor (GHSR-1a) and amplifies the GH pulse, while also blunting somatostatin (the body's "brake" on GH).

Because these are two complementary levers on the same gland, ipamorelin is frequently combined with a GHRH peptide: the GHRH analog primes the pulse and ipamorelin amplifies it. Research and practice suggest the combination produces a larger GH pulse than either alone — though the precise "2-3x" figures often quoted are extrapolations from GH physiology, not head-to-head human trials of ipamorelin.

How long it lasts

In the one human pharmacokinetic study, ipamorelin behaved as you would expect from its structure: dose-proportional kinetics, a terminal half-life of about 2 hours, and a single GH pulse peaking roughly 40 minutes (~0.67 h) after dosing.^[3] That short half-life and pulsatile release are the reason research protocols use small, frequent doses rather than one large daily dose — the goal is to mimic the body's naturally pulsatile GH rhythm.

Read this first. Ipamorelin's benefits fall into two very different evidence buckets. One thing is genuinely established: it releases growth hormone in humans. Everything downstream of that — muscle, fat loss, sleep, anti-aging — is inferred from what GH and IGF-1 do in the body, supported by animal data, but not demonstrated in human outcome trials of ipamorelin itself. In fact, the one controlled human efficacy trial that was run did not meet its goal. We will be explicit about which is which.

What is actually proven in humans

1) It releases growth hormone (human evidence). In a Phase 1 dose-escalation study in healthy men, ipamorelin produced a clear, dose-related GH pulse, with a half-maximal GH-stimulating concentration (SC50) of 214 nmol/L.^[3] This is the one link in the chain confirmed directly in people: give ipamorelin, get a GH pulse.

2) It is selective (preclinical evidence). The GH pulse comes without meaningful cortisol, ACTH, or prolactin elevation — the finding that earned it the "first selective secretagogue" label.^[1] This is animal and cell data, but it is the mechanistic backbone of its favorable reputation.

3) The one human efficacy trial was negative — an important honesty check. In a double-blind, placebo-controlled Phase 2 trial of 114 bowel-resection patients, intravenous ipamorelin (0.03 mg/kg twice daily) did not significantly speed recovery of gut function: median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo (p=0.15, not statistically significant). It was well tolerated, but it did not beat placebo on its primary endpoint.^[4] Any page implying ipamorelin has "proven" human benefits is glossing over this result.

What is plausible but not proven in humans

The following are the benefits ipamorelin is popular for. Each is biologically reasonable given that ipamorelin raises GH — and, through the liver, IGF-1 — but none has been demonstrated in a human outcome trial of ipamorelin. Treat them as hypotheses grounded in GH physiology, not established results.

• Muscle growth & recovery. GH and IGF-1 support muscle protein synthesis, nitrogen retention, and satellite-cell activity. The logic: more of your own GH could aid lean mass and recovery. The gap: no human trial has measured muscle or strength outcomes with ipamorelin. Related compounds are covered under peptides for muscle growth.
• Fat loss. GH is lipolytic — it promotes breakdown of stored triglycerides and favors fat oxidation, with a particular reputation for visceral (abdominal) fat. The logic follows directly from GH biology. The gap: this has not been quantified for ipamorelin in humans; any fat loss also depends heavily on diet and training.
• Sleep quality. The body's largest natural GH pulse occurs during slow-wave (deep) sleep, and bedtime dosing is timed to reinforce it. Many users report deeper sleep, often within the first week. The gap: these are anecdotal reports, not controlled sleep-lab data for ipamorelin.
• Anti-aging. "Somatopause" — the gradual, age-related decline in GH — tracks with more body fat, less muscle, thinner skin, and lower bone density. Restoring a more youthful GH pulse is the rationale. The gap: partially restoring GH pulses is not the same as reversing aging outcomes, and that leap has not been tested for ipamorelin. See anti-aging peptides for the wider context.

The bone-growth study people cite (it is animal data)

One frequently referenced result: in adult female rats, ipamorelin (18, 90, or 450 mcg/day subcutaneously, three times daily for 15 days) produced a dose-dependent increase in longitudinal bone growth rate — from 42 mcm/day in controls up to 52 mcm/day at the top dose (p<0.0001).^[2] This is a clean, real result, but it is a rat study. It supports the idea that ipamorelin drives biologically meaningful GH activity; it does not establish bone or growth benefits in humans.

Bottom line on benefits

Ipamorelin credibly raises your own GH in humans, cleanly. Whether that GH pulse translates into the body-composition, sleep, and anti-aging results people want has not been proven in human trials — and the one efficacy trial that existed came up short for its specific surgical endpoint. That is not a reason to dismiss it, but it is a reason to keep expectations honest and to weigh the research-only status before deciding it is right for you.

Important framing: the doses below are drawn from the research literature and from how the compound is studied — they are not medical advice or an approved regimen, because no approved ipamorelin product or dosing label exists. Ipamorelin's short (~2 hour) half-life and pulsatile GH release^[3] are why protocols favor small, frequent, fasted doses rather than one large dose.

Protocol ranges by experience

Protocol	Dose	Frequency	Timing	Notes
Conservative start	100-200 mcg	1x daily	Bedtime, fasted	Lowest-commitment way to assess tolerance
Standard	200-300 mcg	2-3x daily	Fasted; bedtime is the priority dose	Most commonly referenced range
Higher	300-500 mcg	2-3x daily	Fasted; bedtime priority	Older or more GH-deficient adults; diminishing returns above this
With CJC-1295 (no DAC / Mod GRF 1-29)	200 mcg ipamorelin + 100 mcg CJC	2-3x daily	Same fasted injection	Most common GH-peptide stack in research settings

Going above roughly 500 mcg per dose does not reliably produce more GH — the pituitary's per-pulse response saturates, so extra peptide is mostly wasted. More frequent moderate pulses (mimicking natural rhythm) is the rationale behind multiple daily doses rather than one large one.

Why fasted timing matters

Food — especially carbohydrates and fats — raises insulin and post-meal somatostatin, both of which suppress GH release at the pituitary. Eating shortly before or after a dose can substantially blunt the GH pulse. The standard practical rule researchers use: no food for about 2 hours before the injection and 30 minutes after.

• Bedtime (most important): at least 2 hours after dinner; reinforces the largest natural GH pulse during deep sleep.
• Morning fasted: on waking, before breakfast — a reasonable second dose.
• Pre-workout fasted: pairs with the exercise-induced GH pulse if a third dose is used.

Reconstitution math (worked example)

Ipamorelin ships as a lyophilized (freeze-dried) powder, usually in 2 mg, 5 mg, or 10 mg vials. You add bacteriostatic water to dissolve it, then draw doses on an insulin syringe (100 units = 1 mL).

Worked example — a 5 mg vial reconstituted with 2.5 mL of bacteriostatic water:

• Total peptide = 5 mg = 5,000 mcg.
• Concentration = 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL (i.e., 20 mcg per unit on a 100-unit syringe).
• A 200 mcg dose = 200 ÷ 2,000 = 0.10 mL = 10 units.
• A 300 mcg dose = 300 ÷ 2,000 = 0.15 mL = 15 units.

Vial	BAC water	Concentration	200 mcg dose	300 mcg dose
2 mg	1 mL	2,000 mcg/mL	0.10 mL (10 units)	0.15 mL (15 units)
2 mg	2 mL	1,000 mcg/mL	0.20 mL (20 units)	0.30 mL (30 units)
5 mg	2.5 mL	2,000 mcg/mL	0.10 mL (10 units)	0.15 mL (15 units)
5 mg	5 mL	1,000 mcg/mL	0.20 mL (20 units)	0.30 mL (30 units)
10 mg	5 mL	2,000 mcg/mL	0.10 mL (10 units)	0.15 mL (15 units)

Use the peptide calculator to check volumes for your exact vial, and the reconstitution guide for technique. A higher water volume (lower concentration) makes small doses easier to measure accurately.

Cycle length and monitoring

Unlike hexarelin, ipamorelin is not known for rapid receptor desensitization, so the same dose tends to keep working across a typical cycle. Common research-style structures:

• Standard cycle: 8-12 weeks on, followed by 4-8 weeks off.
• Longer runs: some protocols continue past 12 weeks; if so, periodic IGF-1 bloodwork is the sensible way to track response and avoid pushing IGF-1 too high.
• Stacking note: the no-DAC form of CJC-1295 (Mod GRF 1-29) is the usual partner. The DAC version is a different, much longer-acting molecule with a different profile — do not treat the two as interchangeable.

Storage

• Lyophilized vials: refrigerate (2-8°C) short-term, or freeze (-20°C) for long-term storage.
• Reconstituted solution: refrigerate at 2-8°C and use within about 28 days; do not freeze-thaw.
• Protect from light. See the peptide storage guide for full handling.

Takeaway: in the human data that exists, ipamorelin was well tolerated, and its class is generally considered well tolerated. The catch is that "well tolerated in short trials" is not the same as "proven safe long-term" — there are no long-term human safety studies, and the class carries two real watch-items: blood sugar and a theoretical cancer concern tied to GH/IGF-1.

What the human data showed

In the 114-patient Phase 2 trial, adverse events occurred in 87.5% of the ipamorelin group versus 94.8% of the placebo group — i.e., ipamorelin did not increase side effects relative to placebo, and was described as well tolerated.^[4] The healthy-volunteer PK study likewise reported no notable safety concerns at the doses tested.^[3] These are short-term data in specific populations, not long-term safety proof.

Reported side effects

Side effect	Frequency	Severity	Notes
Injection-site reactions	Common	Mild	Redness or irritation; standard for subcutaneous injections
Head rush / flushing / lightheadedness	Common (early)	Mild	Usually transient, first few doses
Water retention	Occasional	Mild	Puffiness in hands or face; a GH-class effect that eases with dose reduction
Mild hunger	Occasional	Mild	Via the ghrelin receptor, but far less than GHRP-6
Numbness / tingling	Occasional	Mild	GH-related fluid shifts in the extremities
Joint stiffness	Rare	Mild	A GH-class effect, more likely at higher doses

The standout point, well supported by the original characterization, is what ipamorelin generally does not do: it does not significantly raise cortisol, ACTH, or prolactin at GH-releasing doses.^[1] That is the basis for its "clean" reputation versus GHRP-6 and GHRP-2.

The two class-level watch-items

A narrative review of GH secretagogues concluded the class is generally well tolerated, with two caveats worth taking seriously:^[5]

• Blood sugar / insulin sensitivity. GH has anti-insulin effects, so GH secretagogues can nudge blood glucose up and reduce insulin sensitivity. Anyone with diabetes or prediabetes should monitor blood glucose. Because ipamorelin works through your own feedback-regulated GH rather than flooding the system with exogenous GH, this risk is generally considered lower than with injected GH — but it is not zero.
• Long-term cancer question (theoretical, unresolved). GH and IGF-1 are growth-promoting, which raises a theoretical concern about supporting existing malignancy over the long term. This has not been resolved either way for GH secretagogues, which is exactly why active cancer is treated as a contraindication.

Who should not use it (contraindications)

• Active cancer: GH/IGF-1 are growth-promoting; GH-elevating agents are contraindicated with active malignancy.^[5]
• Pituitary disorders or acromegaly: conditions of GH excess should not be further stimulated.
• Diabetic retinopathy: GH elevation may worsen proliferative retinopathy.
• Pregnancy and breastfeeding: no safety data; avoid.

Interactions and what to do

• Insulin / oral diabetes medication: monitor blood glucose, since GH opposes insulin.^[5]
• Glucocorticoids (e.g., prednisone): may blunt the GH response to ipamorelin.
• Food (especially carbs): eating within ~2 hours before a dose suppresses the GH pulse — a practical "interaction" worth respecting.

If you experience persistent water retention, joint aches, or numbness/tingling, these usually reflect too high a GH signal and typically ease with a dose reduction or a break. For general context, see Are Peptides Safe?

Honest status first. There is no FDA-approved ipamorelin product. It never completed Phase 3 and was never approved for any indication. On the regulatory side, the FDA placed ipamorelin in Category 2 of its interim 503A bulk drug substances list in 2023 — the category of substances that may not be used in 503A compounded human drugs. The nomination was later withdrawn (September 2024) and slated for further advisory-committee review. The practical bottom line for a health-decision page: as of this review, ipamorelin is a research/compounding-restricted compound, not a legally compoundable bulk substance and not an approved therapy. For the full picture, see Are Peptides Legal?

Because it is sold as an unregulated research chemical, product quality varies enormously between suppliers — and quality is arguably a bigger real-world risk than the peptide's own pharmacology. What to look for:

Quality indicators

• Third-party Certificate of Analysis (COA): HPLC purity (look for ≥98%) plus mass-spectrometry identity confirming the correct molecule.
• Batch-specific testing: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended for injection.
• Proper packaging: lyophilized powder in sealed, light-protected vials.

Red flags

• No COA, or a COA from the seller rather than an independent lab.
• Pre-mixed liquid "ipamorelin" (shorter shelf life, higher contamination risk).
• Prices far below the market.
• "For human use" or health-benefit labeling — which is non-compliant for a research chemical and signals a vendor cutting corners.

Cost orientation

Research-grade ipamorelin is typically sold in 5 mg or 10 mg vials. At a common 200-300 mcg-per-dose research range, a single 10 mg vial contains many doses, so the per-dose cost is usually modest; bacteriostatic water and insulin syringes are small additional expenses. Cost should never be the deciding factor over COA-verified quality.

Ipamorelin sits in a family of GH-releasing peptides that split into two mechanisms: ghrelin-receptor agonists (ipamorelin, GHRP-6, GHRP-2, hexarelin) and GHRH analogs (sermorelin, CJC-1295). The table below compares the ghrelin-receptor group, where ipamorelin's selling point is selectivity.

Effect	Ipamorelin	GHRP-6	GHRP-2	Hexarelin
Cortisol / ACTH increase	Minimal	Moderate	Moderate	Significant
Prolactin increase	Minimal	Moderate	Moderate	Significant
Hunger	Mild	Severe	Moderate	Mild
Desensitization with use	Slow	Moderate	Moderate	Rapid

Ipamorelin's minimal off-target hormonal footprint is the reason it is usually the preferred ghrelin-receptor peptide for longer or cleaner protocols. Hexarelin releases GH most potently but carries the most off-target effects and the fastest tolerance.

Against the GHRH side: sermorelin and CJC-1295 work through a different receptor and are complementary rather than competitive — which is why ipamorelin is so often stacked with one of them. See the full head-to-head guides: Sermorelin vs Ipamorelin, Ipamorelin vs GHRP-6, and Hexarelin vs Ipamorelin. For stacking, see the GH Optimization Stack.